Restricted accessResearch articleFirst published online 2008-7
Indagine epidemiologica relativa alla prevenzione e terapia delle alterazioni del metabolismo calcio-fosforo nel paziente uremico in trattamento emodialitico in Toscana
NKF-K-DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis2003; 44(suppl 3).
2.
YoungE.W., AlbertM.J., SatayatumS.Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int2005; 67: 1171–87.
3.
YoungE.W., AkibaT., AlbertJ.M.Magnitude and impact of abnormal mineral metabolism in the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Kidney Dis2004; 44: 34–8.
4.
Fernàndez-MartinJ., GorrizJ., KettelerM.Achievement of K/DOQI targets in European hemodialysis patients in the COSMOS study: differences between prevalent and incident patients. Presented at: Renal Week, 8–13 November 2006; Philadelphia.
5.
Cannata-AndiaJ.B., CarreraF.The pathophysiology of secondary hyperparathyroidism and the consequences of uncontrolled mineral metabolism in chronic kidney disease: the role of COSMOS. Nephrol Dial Transplant Plus2008; 1(suppl 1): S2–6.
6.
AndressD.L., NorrisK.C., CoburnJ.W., LevineB.Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med1989; 321: 274–9.
7.
MalbertiF., SurianM., CosciP.Effect of chronic intravenous calcitriol on parathyroid function and set-point of calcium in dialysis patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant1992; 7: 822–8.
8.
LachF., HervasJ., CerezoS.The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism. Am J Kidney Dis1995; 26: 845–51.
9.
SpragueS.M., LiachF., AmdahlM.Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int2003; 63(4): 1483–90.
10.
MittmanN., KhannaR., ChattopadhyayJ.Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: a single center cross-over study. Kidney Int2006; 70(suppl): S64–7.
11.
CoyneD., AcharyaM., QiuP.Paricalcitol capsule for the teatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis2006; 47: 263–76.
12.
MessaP.G., MacarioF., YaqoobM.The OPTIMA Study: Assessing a new Cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol2008; 3: 36–45.
ChoncolM., WuthrichR.P.Potential future uses of calcimimetics in patients with chronic kidney disease. Nephrol Dial Transplant2008; 1(suppl 1): S36–41.
15.
MazzaferroS., CozzolinoM., MarangellaM.Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology. G Ital Nefrol2007; 24(suppl 37): S107–24.
16.
SlatopolskyE., FinchJ., RitterC.A new analog of calcitriol,19-Nor-1,25-(OH)2D2 suppresses parathyroid hormone secretion in uremic rats in the absence of hyperpcalcemia. Am J Kidney Dis1995; 26: 852–60.
17.
TengM., WolfM., LowrieE.Survival of patients un-dergoing hemodialysis with paracalcitol or calcitriol therapy. N Engl Med2003; 349(5): 446–56.
18.
Kalantar-ZadehK., KuwaeN., RegidorD.L.Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int2006; 70: 771–80.
19.
MalbertiF., MarcelliD., ConteF.Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol2001; 12: 1242–8.
20.
KestenbaumB., AndressD.L., SchwartzM.Parathyroidectomy rates among United States dialysis patients: 1990–1999. Kidney Int2004; 65: 282–88.
